June 2024 - Page 6 of 16

Copy of ASCO China Voice | Professor Pei Dong Leads Multiple Breakthrough Studies at the ASCO Conference

By Mourabit Halima 2024.06.18

The 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) was grandly held in Chicago, USA, from May 31 to June 4, 2024. As a premier global event, ASCO gathers oncology experts from around the world to discuss the latest advancements and future trends in the field. At this year's ASCO conference, several studies led by Professor Pei Dong from the Sun Yat-sen University Cancer Prevention and Treatment Center were selected, making a significant impact on the international stage. These studies not only represent new progress in the field of urologic oncology in China but also contribute to the global development of urologic oncology. "Oncology Frontier" has summarized these studies for our readers.

EASL China Voice丨Professor Wei Lu ‘s Team Presents Four Research Findings at EASL 2024

By Mourabit Halima 2024.06.17

The European Association for the Study of the Liver (EASL) Annual Meeting was successfully held in Milan, Italy, from June 5 to 8, 2024. During the conference, four research posters from Professor Wei Lu 's team at the Hepatobiliary Tumor Department of Tianjin Medical University Cancer Institute and Hospital were presented. These studies cover the fields of liver cancer, cholangiocarcinoma, and liver cirrhosis. This report provides an overview of their findings for our readers.

Crossing Mountains and Seas, Reaching Further—Professor Man Li Shares Highlights of HR+ Advanced Breast Cancer Research at ASCO

By Mourabit Halima 2024.06.17

Hormone receptor-positive (HR+) breast cancer accounts for about 70% of all breast cancers. With endocrine therapy as the foundation, chemotherapy, targeted therapy, novel antibody-drug conjugates (ADCs), and immune checkpoint inhibitors (ICIs) provide a wealth of treatment options for HR+ advanced breast cancer patients, also offering more potential combinations for clinical practice. In this "Man Talks Breast Cancer: ASCO Special," Professor Man Li's team from The Second Affiliated Hospital of Dalian Medical University has selected the latest ASCO studies on HR+ advanced breast cancer, covering topics such as cross-line treatment with CDK4/6 inhibitors, novel ADCs combined with ICIs, and comparing CDK4/6 inhibitors + ET with chemotherapy in premenopausal women. These can provide more valuable insights for clinical practice.

Exploring a New Neoadjuvant Strategy with Toripalimab Combined with Chemotherapy to Further Improve Survival Benefits for MIBC Patients

By Mourabit Halima 2024.06.17

For patients with muscle-invasive bladder cancer (MIBC), when the tumor is large, deeply invasive, or has local lymph node metastasis, the radicality of whole bladder surgery can be affected. Neoadjuvant therapy can enhance the rate of radical resection by downstaging the tumor, and it has become a current research hotspot. At this year's ASCO Annual Meeting in Chicago, USA, a study led by Professor Hongqian Guo's team from Nanjing Drum Tower Hospital was selected, exploring a new neoadjuvant treatment strategy with toripalimab combined with chemotherapy for MIBC patients. "Oncology Frontier" invited Professor Shun Zhang from Nanjing Drum Tower Hospital to share the relevant content on-site.

ASCO Expert Interview丨Professor Qingqing Cai: CHESS Results Unveiled, Exploring “Chemo-Less” Treatment for Mantle Cell Lymphoma

By Lin Zhang 2024.06.17

The Phase II multicenter clinical trial (CHESS chemo-less, NCT04624958) aims to explore the efficacy and safety of zanubrutinib combined with rituximab followed by a short course of cytarabine-based chemotherapy, then maintained with zanubrutinib in newly diagnosed mantle cell lymphoma (MCL) patients. The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was grandly held in Chicago from May 31 to June 4. The study results of "Zanubrutinib Combined with Rituximab Followed by Short Course R-DHAOx Therapy in MCL Patients: Phase II CHESS Clinical Trial" were presented as a poster. Hematology Frontier invited the first author of the study, Professor Qingqing Cai from Sun Yat-sen University Cancer Center, to interpret the study and share insights into the progress in MCL diagnosis and treatment.

Professor Kun Wang: The NeoMDSS Model Accurately Predicts pCR Rates after Neoadjuvant Therapy for Breast Cancer, Enhancing Personalized Treatment

By Mourabit Halima 2024.06.17

Breast cancer is a malignant tumor that seriously threatens women's health. Neoadjuvant therapy is a crucial means to provide more surgical opportunities and pave the way for a cure. However, the pathological complete response (pCR) varies significantly with different molecular subtypes and treatment regimens, making it challenging to predict treatment efficacy early in neoadjuvant therapy for individual patients. From May 31 to June 4, 2024, the American Society of Clinical Oncology (ASCO) Annual Meeting was grandly held. At the meeting, Professor Kun Wang's team from Guangdong Provincial People's Hospital presented a study on a model called NeoMDSS, which predicts the effectiveness of neoadjuvant therapy for breast cancer based on MRI and other clinical pathological parameters. Oncology Frontier interviewed Professor Kun Wang to share the main results and clinical significance of this study.

ASCO Voice of China丨Professor Ying Fan: Breaking the mTNBC 2L+ Treatment Ceiling, China’s First TROP2 ADC, LuKangsa-Tropozumab, Leads to Longer PFS Benefits

By Mourabit Halima 2024.06.16

The 60th American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31 to June 4, 2024, in Chicago, USA. During the meeting, Professor Binghe Xu from the Chinese Academy of Medical Sciences Cancer Hospital presented groundbreaking results from the phase III OptiTROP-Breast01 study of China's first original TROP2 ADC, LuKangsa-Tropozumab (SKB264). This study, led by Professor Xu, primarily targeted advanced triple-negative breast cancer (TNBC) in China and showed that LuKangsa-Tropozumab achieved a median progression-free survival (PFS) of 6.7 months, an objective response rate (ORR) of 45.4%, and a significant improvement in overall survival (OS), making it the current TROP2 ADC with the best mPFS for TNBC. In this edition of "ASCO Voice of China," Professor Ying Fan shares insights into this pioneering achievement

EASL 2024 Hot Review | Professor Hai Li: The Role of Immunosuppression and Microbiome Variations in Liver Disease Progression

By Mourabit Halima 2024.06.16

Acute-on-chronic liver failure (ACLF) is a complex syndrome characterized by acute deterioration of liver function in patients with chronic liver disease, accompanied by high mortality rates due to liver and extrahepatic organ failure. The short-term mortality rate of medical comprehensive treatment for ACLF can reach 50% to 90%. Given the high mortality and complex pathogenesis, research and treatment strategies for ACLF are particularly important. At the 2024 European Association for the Study of the Liver (EASL) Annual Meeting, Professor Hai Li from Renji Hospital, affiliated with Shanghai Jiao Tong University, provided insightful commentary on three significant research findings in the ACLF field. These studies delve into the roles and effects of immunosuppression and microbiome variations in acute decompensation (AD) of cirrhosis and ACLF, offering new perspectives for understanding the complex mechanisms of liver disease progression and potential targets for developing new ACLF treatment strategies.

Five-Year Follow-Up Results of CD19 and CD22 CAR-T Combined Therapy for Relapsed B-ALL Post-Allogeneic Hematopoietic Stem Cell Transplantation

By Lin Zhang 2024.06.16

The 29th Annual Meeting of the European Hematology Association (EHA 2024) will be grandly held in Madrid, Spain, from June 13 to 16, 2024! As an international event in the field of hematology, EHA 2024 gathers top hematology experts worldwide to share and discuss the latest research findings in hematology. This issue features a research report from Director Shuangyou Liu’s team at Beijing Gaobo Boren Hospital, detailing the five-year follow-up results of CD19 and CD22 CAR-T combined therapy for relapsed acute B-lymphoblastic leukemia (B-ALL) post-allogeneic hematopoietic stem cell transplantation.

Professor Wenyan Chen: Perseverance and Commitment—10-Year Follow-Up Results of the Phase III PANTHER Trial

By Mourabit Halima 2024.06.16

Numerous studies have confirmed the clinical value of postoperative adjuvant chemotherapy for early-stage breast cancer patients. However, the cardiotoxicity and hematologic adverse reactions associated with high-dose chemotherapy remain significant clinical challenges. Recently, the ESMO BC 2024 conference released the 10-year follow-up results of the PANTHER trial, an important study on the treatment of high-risk early breast cancer. This study revealed the efficacy differences between dose-dense tailored adjuvant chemotherapy and standard adjuvant chemotherapy, providing in-depth insights into the response of key subgroups. Oncology Frontier invited Professor Wenyan Chen from Nanchang People's Hospital to elaborate on the background, findings, clinical significance, and implications of this research.